Clinical Trial Update: Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial [Phase 2]

View source ↗

Summary

A Phase 2, open-label, single-arm trial evaluating Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) for newly diagnosed Splenic B-cell Lymphoma with prominent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Splenic B-cell Lymphoma with Prominent Nucleoli

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN | Phase 2 | Status: RECRUITING